分子时代的肺炎实验室诊断
本文综述分子诊断技术在肺炎病原学检测中的应用进展。传统微生物方法鉴定致病菌面临挑战,分子检测的发展是近年呼吸道病原诊断的重要进步,但肺部微生物组研究提示肺炎涉及微生态失调,新诊断技术信息尚待充分理解,有望改善抗生素治疗时机、靶向选择与降阶梯管理。
要点
- 分子诊断技术是近年肺炎病原学检测的重要进展
- 肺部是动态微生物生态系统,肺炎涉及微生态失调
- 新诊断技术有望缩短用药时间并促进抗生素管理
核心结论
- 分子诊断技术为肺炎病原学诊断带来重要进步,但肺部微生物组新认识提示肺炎概念涉及微生态失调,新诊断技术的信息价值仍需深入学习。
研究设计与样本
- 本文为综述,提供分子时代肺炎实验室诊断方法的概述。
主要发现
- 传统微生物学方法鉴定肺炎致病菌面临巨大挑战。
- 分子诊断检测的发展与实施是近年呼吸道病原微生物诊断的重大进展。
- 肺部是动态微生物生态系统,肺炎涉及肺部微生物组的失调或改变。
临床怎么用
- 新诊断技术有望改善抗生素治疗时机、靶向抗生素选择及更有效的降阶梯与抗生素管理。
局限性
- 当前肺炎概念因微生物组新知识而不完全符合实际,新诊断技术提供的信息仍需大量学习。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pneumonia remains a worldwide health problem with a high rate of morbidity and mortality. Identification of microbial pathogens which cause pneumonia is an important area for optimum clinical management of pneumonia patients and is a big challenge for conventional microbiological methods. The development and implementation of molecular diagnostic tests for pneumonia has been a major advance in the microbiological diagnosis of respiratory pathogens in recent years. However, with new knowledge regarding the microbiome, together with the recognition that the lungs are a dynamic microbiological ecosystem, our current concept of pneumonia is not totally realistic as this new concept of pneumonia involves a dysbiosis or alteration of the lung microbiome. A new challenge for microbiologists and clinicians has therefore arisen. There is much to learn regarding the information provided by this new diagnostic technology, which will lead to improvements in the time to antibiotic therapy, targeted antibiotic selection and more effective de-escalation and improved stewardship for pneumonia patients. This article provides an overview of current methods of laboratory diagnosis of pneumonia in the molecular age.
引用
- Torres A, Lee N, Cilloniz C, et al. Laboratory diagnosis of pneumonia in the molecular age. Eur Respir J. 2016. PMID: 27811073. doi:10.1183/13993003.01144-2016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。